RBC Capital Markets sees a $25 billion market opportunity for the space.
The average analyst rating is hold, with 8% upside to the average analyst price target, according to FactSet.
Eli Lilly has an average analyst rating of overweight and 8.3% upside to the average analyst price target, according to FactSet.
Stock Chart Icon Stock chart icon AstraZeneca's one-year performanceAstraZeneca shares have an average analyst rating of overweight and nearly 6% upside to the average analyst price target, according to FactSet.
Stock Chart Icon Stock chart icon Bristol-Myers Squibb's one-year performance
Persons:
It's, Gregory Renza, Renza, Oppenheimer, Jeff Jones, Piper Sandler, Edward Tenthoff, Eli Lilly, Dan Lyons, Janus Henderson, Myers Squibb, William Blair, Matt Phipps, Jefferies, Andrew Tsai, They've, Janus Henderson's Lyons, Jones, Piper Sandler's Tenthoff, Myers
Organizations:
pharma, RBC Capital Markets, TRT, Novartis, Mariana Oncology, Janus, Janus Henderson Investors, Bristol, RayzeBio, Karuna Therapeutics, AstraZeneca, Fusion Pharmaceuticals, GlobalData's Pharma Intelligence, Pluvicto
Locations:
Mariana, Bristol